Osimertinib approved for untreated EGFR mutation-positive NSCLC
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults..
Read more on the National Institute for Care and Health Excellence website